POP1

Ribonucleases P/MRP protein subunit POP1 · Q99575 · POP1 on Sugi Atlas →

0 patent compounds predicted against POP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to POP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer PHASE3COMPLETED
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer PHASE2WITHDRAWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI PHASE1/PHASE2UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer PHASE2COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer PHASE2UNKNOWN
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes nanUNKNOWN
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Study of Specimens From Young Patients With Neuroblastoma nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Genetic Basis of Mitral Valve Prolapse nanUNKNOWN
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. nanUNKNOWN
Genetic and Phenotypic Characteristics of Mitral Valve Prolapse nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a POP1 binder may also engage these)

ProteinNameSimilarity
F4IL30 0.978 F4IL30 →
TRMT1L tRNA (guanine(27)-N(2))-dimethyltransferase 0.978 landscape →
Q15061 0.977 Q15061 →
Q6NVF4 0.977 Q6NVF4 →
Q5M954 0.976 Q5M954 →
F1ND48 0.976 F1ND48 →
Q9R207 0.976 Q9R207 →
Q8NE18 0.975 Q8NE18 →
Q3ZAU7 0.975 Q3ZAU7 →
Q6P7W5 0.975 Q6P7W5 →
Q80U93 0.975 Q80U93 →
Q7TPQ3 0.974 Q7TPQ3 →
Q96AY2 0.974 Q96AY2 →
Q3US16 0.974 Q3US16 →
D2HNY3 0.974 D2HNY3 →
Q8BW70 0.974 Q8BW70 →
Q5JTW2 0.974 Q5JTW2 →
Q8N309 0.974 Q8N309 →
Q14B46 0.974 Q14B46 →
Q5R5T0 0.973 Q5R5T0 →
Q8CE96 0.973 Q8CE96 →
Q1LWH4 0.973 Q1LWH4 →
Q86WB0 0.973 Q86WB0 →
Q9Y2M0 0.973 Q9Y2M0 →
Q9JIL9 0.973 Q9JIL9 →
Q4R6Y8 0.973 Q4R6Y8 →
Q8C0M0 0.973 Q8C0M0 →
Q86VS3 0.973 Q86VS3 →
Q496Z9 0.973 Q496Z9 →
Q1T7C0 0.972 Q1T7C0 →